Biogen Inc.
Biogen Reports 1% GAAP EPS Growth and 8% Non-GAAP EPS Growth in Q1 2024
Summary
On April 24, 2024, Biogen Inc. announced its first quarter 2024 financial results, reporting a 1% growth in GAAP earnings per share (EPS) and an 8% growth in Non-GAAP EPS. Total revenue for the quarter was $2.3 billion, with GAAP diluted EPS at $2.70 and Non-GAAP diluted EPS at $3.67. Despite a 7% decrease in total revenue and a 3% decrease in product revenue, the company saw significant improvements in gross and operating margins, primarily due to the Fit for Growth program and R&D prioritization. Biogen also launched several new products, including LEQEMBI, SKYCLARYS, and ZURZUVAE, which showed promising uptake. The company reaffirmed its full-year 2024 financial guidance, expecting Non-GAAP EPS to grow approximately 5% at the mid-point, with total revenue anticipated to decline by a low- to mid-single digit percentage compared to 2023.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement